Puma Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| PBYI Stock | USD 3.39 0.12 3.67% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter 2.13678797 | Current Value 2.24 | Quarterly Volatility 46.94121229 |
Check Puma Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Puma Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 14 M, Other Operating Expenses of 174.6 M or Operating Income of 34.3 M, as well as many indicators such as Price To Sales Ratio of 0.91, Dividend Yield of 0.0 or PTB Ratio of 3.63. Puma financial statements analysis is a perfect complement when working with Puma Biotechnology Valuation or Volatility modules.
Puma | Dividend Paid And Capex Coverage Ratio |
Latest Puma Biotechnology's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Puma Biotechnology over the last few years. It is Puma Biotechnology's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Puma Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (20.95) | |
| Coefficient Of Variation | (224.05) | |
| Mean Deviation | 33.93 | |
| Median | (2.63) | |
| Standard Deviation | 46.94 | |
| Sample Variance | 2,203 | |
| Range | 204 | |
| R-Value | 0.40 | |
| Mean Square Error | 1,998 | |
| R-Squared | 0.16 | |
| Significance | 0.14 | |
| Slope | 4.17 | |
| Total Sum of Squares | 30,849 |
Puma Dividend Paid And Capex Coverage Ratio History
About Puma Biotechnology Financial Statements
Investors use fundamental indicators, such as Puma Biotechnology's Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Puma Biotechnology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | 2.14 | 2.24 |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out the analysis of Puma Biotechnology Correlation against competitors. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.